Diogo Jesus, C. Henriques, Ana Matos, Andrea Doria, L. Inês
{"title":"P67 系统性红斑狼疮-生活质量评估系统(SLE-DAS)可轻松识别疾病活动严重、健康相关生活质量较差的系统性红斑狼疮患者:阿尼洛单抗2期和3期临床试验事后研究的推导与验证","authors":"Diogo Jesus, C. Henriques, Ana Matos, Andrea Doria, L. Inês","doi":"10.1136/lupus-2024-el.121","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20386,"journal":{"name":"Poster presentations","volume":"44 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials\",\"authors\":\"Diogo Jesus, C. Henriques, Ana Matos, Andrea Doria, L. Inês\",\"doi\":\"10.1136/lupus-2024-el.121\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20386,\"journal\":{\"name\":\"Poster presentations\",\"volume\":\"44 7\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster presentations\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/lupus-2024-el.121\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster presentations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/lupus-2024-el.121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
P67 The SLE-DAS enables easy identification of SLE patients with severe disease activity and worse health-related quality of life: derivation and validation in post-hoc study of anifrolumab phase 2 and 3 clinical trials